MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Vir Biotechnology Inc

Fechado

SetorSaúde

5.92 -8.5

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.85

Máximo

6.47

Indicadores-chave

By Trading Economics

Rendimento

109M

-105M

Vendas

8.9M

11M

EPS

-0.76

Margem de lucro

-927.372

Funcionários

408

EBITDA

97M

-118M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+417.8% upside

Dividendos

By Dow Jones

Próximos Ganhos

1 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-385M

919M

Abertura anterior

14.42

Fecho anterior

5.92

Sentimento de Notícias

By Acuity

50%

50%

180 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Vir Biotechnology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de nov. de 2024, 03:00 UTC

Principais Notícias

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

Comparação entre Pares

Variação de preço

Vir Biotechnology Inc Previsão

Preço-alvo

By TipRanks

417.8% parte superior

Previsão para 12 meses

Média 32 USD  417.8%

Máximo 110 USD

Mínimo 14 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Vir Biotechnology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

7

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

6.15 / 7.01Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

180 / 386 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.